CORT — Corcept Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $12.26bn
- $11.94bn
- $761.41m
Corcept Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Corcept Therapeutics Q3 EPS USD 0.41 Vs. IBES Estimate USD 0.28
U.S. RESEARCH ROUNDUP- Autozone, Costco Wholesale, Walmart
U.S. RESEARCH ROUNDUP- Hubspot, McDonald's, Tesla
Brief: Corcept Therapeutics Q2 EPS USD 0.32 Vs. IBES Estimate USD 0.23
Corcept Therapeutics Inc expected to post earnings of 23 cents a share - Earnings Preview
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
U.S. STOCKS ON THE MOVE-Sarepta, Moderna, Merus
U.S. STOCKS ON THE MOVE-Riot Platforms, Nvidia, Dell
Corcept rises as hormone disorder drug succeeds in late-stage study
Corcept Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Corcept Therapeutics Q1 EPS USD 0.25 Vs. IBES Estimate USD 0.22
Brief: Corcept Therapeutics Targets Year-End For Catalyst Treatment Data Release
U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. STOCKS ON THE MOVE-AZZ, Smartsheet, Zions Bancorporation
Corcept falls on limited data from late-stage trial of Cushing's syndrome drug
Brief: Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
Brief: Corcept Completes Enrollment In Late-Stage Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer
Brief: Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome